The city of Rockford dedicated a memorial plaque to one of their own, who died in November to a form of muscular dystrophy.

The FDA’s shift on Elevidys sends a message: boldness, scientific rigor and urgency are essential in confronting rare ...

Insmed’s (INSM) treatment of Duchenne muscular dystrophy, the single-stranded, non-replicating, recombinant adeno-associated virus serotype 9 ...

Echocardiography may be at the vanguard for early and rapid detection of heart issues indicative of Duchenne muscular ...

Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), is pleased to announce the expansion of its leadership team with the ...

The first few months of 2025 brought hope to the rare disease community. Food and Drug Administration leadership promised ...

While it’s established that Duchenne muscular dystrophy (DMD) causes a loss of muscle mass and strength, few studies have examined the gastrointestinal issues tied to DMD.

Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the best small cap stocks with biggest upside potential. On August 4, Dyne ...

WASHINGTON, Aug. 18, 2025 /PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), is pleased to announce ...

Keros Therapeutics, Inc. ('Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and ...

Duchenne is a genetic disorder that slowly robs people of their muscle strength. Parent Project Muscular Dystrophy (PPMD) fights every single battle necessary to end Duchenne.